OR WAIT null SECS
The deal features a long-term supply and production agreement between the parties
Delpharm, a contract development and manufacturing organization (CDMO), has purchased Sandoz Canada’s manufacturing plant in Boucherville, Quebec. According to Sandoz Canada, which is a division of Novartis, the plant is considered the largest sterile injectable production plant in Canada, and provides strategic and potentially lifesaving medicines to both the Canadian and US healthcare systems, predominantly consisting of hospitals.
While all Sandoz Canada injectable products will be made by Delpharm with the same formulations, Sandoz Canada remains the owner of the marketing authorizations and intellectual property, and will continue to have commercial responsibility for all its products. The CDMO plans on investing in the site and wants to pursue business development opportunities for growth.
“We’re pleased to be partnering with a reliable CDMO like Delpharm,” notes Michel Robidoux, Sandoz Canada’s president and general manager. “As part of this acquisition, we’ve signed a long-term agreement for Delpharm to provide Sandoz Canada with continuous supply of medicines manufactured in Boucherville, as well as an agreement maintaining jobs.”